• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator.

作者信息

Williams G A, Lambrou F H, Jaffe G A, Snyder R W, Green G D, Devenyi R G, Abrams G W

机构信息

Department of Ophthalmology, Medical College of Wisconsin, Milwaukee 53226.

出版信息

Arch Ophthalmol. 1988 Aug;106(8):1055-8. doi: 10.1001/archopht.1988.01060140211025.

DOI:10.1001/archopht.1988.01060140211025
PMID:3135790
Abstract

Twenty-five micrograms of human recombinant tissue plasminogen activator (tPA) was injected intracamerally into the eyes of three aphakic patients who developed severe intraocular fibrin formation within 24 hours after vitrectomy surgery. Fluid obtained from gas-fluid exchange specimens taken 24 hours after tPA injection was analyzed for tPA by an enzyme-linked immunosorbent assay and a spectrophotometric solid-phase fibrin assay. In each of the three patients, complete fibrin resolution occurred within four hours after the tPA injection. There were no complications associated with the intraocular tPA injections. There was measurable tPA activity 24 hours after the initial injection ranging from 0.23 to 1.4 micrograms. In contrast, tPA was undetectable in gas-fluid exchange specimens obtained from seven patients who did not receive intraocular tPA injections. Intraocular tPA is an effective means of treating postvitrectomy fibrin formation in selected aphakic patients.

摘要

相似文献

1
Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator.
Arch Ophthalmol. 1988 Aug;106(8):1055-8. doi: 10.1001/archopht.1988.01060140211025.
2
[Tissue plasminogen activator treatment of postvitrectomy pupillary fibrin membrane].
Nippon Ganka Gakkai Zasshi. 1991 Nov;95(11):1124-8.
3
The lowest effective dose of tissue plasminogen activator for fibrinolysis of postvitrectomy fibrin.
Retina. 1992;12(3 Suppl):S75-9. doi: 10.1097/00006982-199212031-00016.
4
The use of tissue plasminogen activator in postvitrectomy cases.
Int Ophthalmol. 1993 Apr;17(2):95-100. doi: 10.1007/BF00942782.
5
Tissue plasminogen activator for postvitrectomy fibrin formation.
Ophthalmology. 1990 Feb;97(2):184-9. doi: 10.1016/s0161-6420(90)32618-0.
6
Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator.
Am J Ophthalmol. 1989 Aug 15;108(2):170-5. doi: 10.1016/0002-9394(89)90013-5.
7
Tissue plasminogen activator for the treatment of postoperative intraocular fibrinous membranes following cataract surgery.组织型纤溶酶原激活剂用于治疗白内障手术后的眼内纤维蛋白膜。
Ger J Ophthalmol. 1995 Mar;4(2):75-9.
8
Clinical use of recombinant plasminogen activator for intraocular fibrinolysis.重组纤溶酶原激活剂在眼内纤维蛋白溶解中的临床应用。
Ger J Ophthalmol. 1992;1(5):354-60.
9
Tissue plasminogen activator in the treatment of vitreoretinal diseases.
Semin Ophthalmol. 2000 Mar;15(1):44-50. doi: 10.3109/08820530009037850.
10
[Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].玻璃体切除术后用组织型纤溶酶原激活剂治疗眼内纤维蛋白形成
Zhonghua Yan Ke Za Zhi. 1995 Jul;31(4):255-8.

引用本文的文献

1
In vitro vitamin K3 effect on conjunctival fibroblast migration and proliferation.体外维生素K3对结膜成纤维细胞迁移和增殖的影响。
ScientificWorldJournal. 2014 Jan 8;2014:916713. doi: 10.1155/2014/916713. eCollection 2014.
2
Tissue plasminogen activator therapy for the eye.眼部组织纤溶酶原激活剂治疗
Br J Ophthalmol. 2005 Nov;89(11):1390-1. doi: 10.1136/bjo.2005.074401.
3
Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.白内障手术后纤维蛋白形成病例中重组组织型纤溶酶原激活剂的应用:一项前瞻性随机多中心研究。
Br J Ophthalmol. 1998 Jul;82(7):810-5. doi: 10.1136/bjo.82.7.810.
4
The use of tissue plasminogen activator in post-traumatic total hyphaema.
Graefes Arch Clin Exp Ophthalmol. 1996 Jan;234(1):67-8. doi: 10.1007/BF00186522.
5
The use of tissue plasminogen activator in postvitrectomy cases.
Int Ophthalmol. 1993 Apr;17(2):95-100. doi: 10.1007/BF00942782.
6
Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.影响抗生素治疗实验性术后眼内炎疗效的因素。
Trans Am Ophthalmol Soc. 1993;91:775-844.
7
Topical treatment of postvitrectomy fibrin formation with tissue plasminogen activator.组织型纤溶酶原激活剂对玻璃体切除术后纤维蛋白形成的局部治疗
Int Ophthalmol. 1994;18(6):351-3. doi: 10.1007/BF00930313.
8
Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.增殖性玻璃体视网膜病变:病理生物学、手术治疗及辅助治疗
Br J Ophthalmol. 1995 Oct;79(10):953-60. doi: 10.1136/bjo.79.10.953.
9
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.组织型纤溶酶原激活剂。其药理学及作为溶栓剂的治疗用途综述。
Drugs. 1989 Sep;38(3):346-88. doi: 10.2165/00003495-198938030-00003.
10
Intravitreal recombinant tissue plasminogen activator in the treatment of experimentally induced bacterial endophthalmitis.玻璃体内注射重组组织型纤溶酶原激活剂治疗实验性诱导的细菌性眼内炎。
Int Ophthalmol. 1991 Mar;15(2):79-86. doi: 10.1007/BF01046426.